Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

for
Clinical Stage III Cutaneous Melanoma AJCC v8,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06075524

Recruiting

Definitive Radiation for High-Risk Spine Metastases

for
Metastatic Cancer, Metastatic Lung Cancer,
Location: Stony Brook NY
Sponsor: Stony Brook University

Sex: All

Age: 18+

Code: NCT06165419

Recruiting

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

for
Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor
Location: Fairfax VA, Sioux Falls SD, Dallas TX
Sponsor: Sorrento Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT04900519

Phase 1, Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

for
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma,
Location: Boston MA, New York NY, Philadelphia PA,
Sponsor: Children's Oncology Group

Sex: All

Age: 1 - 30

Code: NCT04851119

Phase 1, Phase 2, Recruiting

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

for
Advanced Solid Tumors, Metastatic Pancreatic Cancer,
Location: Bethesda MD, Fairway KS
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 12 - 70+

Code: NCT04222413

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

for
Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor,
Location: Boston MA, Bethesda MD, Toronto, Pittsburgh PA,
Sponsor: Ankyra Therapeutics, Inc

Sex: All

Age: 18+

Code: NCT06171750

Phase 1, Recruiting

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

for
Breast Cancer, Solid Tumors, Adult
Location: Boston MA, New York NY, Fairfax VA, Tampa FL,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT05768139

Phase 1, Phase 2, Recruiting

A Study of PYX-201 in Advanced Solid Tumors

for
Solid Tumor, Advanced Solid Tumor
Location: Boston MA, Providence RI, New York NY, Philadelphia PA,
Sponsor: Pyxis Oncology, Inc

Sex: All

Age: 18+

Code: NCT05720117

Phase 1, Recruiting

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma

for
Mesothelin Positive, Mesothelin-Expressing Tumors,
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT06623396

Phase 1, Recruiting

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

for
Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer,
Location: Huntersville NC, Detroit MI, Houston TX,
Sponsor: Qurgen Inc.

Sex: All

Age: 18+

Code: NCT05989724

Phase 1, Recruiting

Imaging of Solid Tumors Using FAP-2286

for
Solid Tumors, Adult, Metastatic Cancer
Location: San Francisco CA
Sponsor: Thomas Hope

Sex: All

Age: 18+

Code: NCT04621435

Phase 1, Recruiting

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

for
Cancer, All Types, Cancer of Liver, Cancer of Stomach,
Location: Gainesville GA
Sponsor: SpeciCare

Sex: All

Age: 0 - 70+

Code: NCT03896958

Recruiting

Clinical Evaluation of Tissue Sampling Bias in Histologic Evaluation of Sentinel Lymph Nodes in Breast Cancer

for
Breast Neoplasms, Breast Diseases
Location: Allentown PA
Sponsor: Sysmex America, Inc.

Sex: All

Age: 18+

Code: NCT01140763

Recruiting

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

for
Advanced Solid Tumor, Unresectable Solid Tumor,
Location: New York NY, Hackensack NJ, Philadelphia PA,
Sponsor: Clasp Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06778863

Phase 1, Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

for
Advanced Solid Tumor, Solid Tumor
Location: New Haven CT, New York NY, Hackensack NJ, Miami FL,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT05981703

Phase 1, Recruiting

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

for
Solid Tumors, ER+ Breast Cancer,
Location: Detroit MI, St Louis MO, Dallas TX, Salt Lake City UT
Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Sex: All

Age: 18+

Code: NCT05490472

Phase 1, Phase 2, Recruiting

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

for
Recurrent Childhood Acute Myeloid Leukemia,
Location: Miami FL
Sponsor: Florida International University

Sex: All

Age: 0 - 21

Code: NCT05857969

Phase 1, Recruiting

Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning

for
Locally Advanced Malignant Solid Neoplasm,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18+

Code: NCT04515810

Recruiting

Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes

for
Cancer, Solid Tumor, Hematologic Malignancy
Location: Indianapolis IN, Martinsville IN
Sponsor: Community Cancer Care

Sex: All

Age: 18+

Code: NCT00300001

Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18+

Code: NCT05098210

Phase 1, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial